BM; skin biopsies; acute GVHD Blood is increasingly used as stem cell source in allogeneic transplantation and particularly for patients with haematological malignancies. The major complication following allogeneic stem cell transplantation is graft-versus-host disease (GVHD) that may lead to severe morbidity and considerable mortality. 1 Blood stem cell (BSC) transplantation was initially supposed to induce more acute GVHD because of a 10-fold higher number of T-lymphocytes. 2, 3 Most randomised studies comparing BSC and bone marrow (BM) transplantation have not supported this hypothesis, [4] [5] [6] [7] [8] [9] but in one of the studies there was a significantly higher incidence of more severe acute GVHD in the BSC group. 10 On the other hand, there are strong indications that BSC recipients develop more severe chronic GVHD compared to BM recipients. [10] [11] [12] Cutaneous rash is the most frequent clinical manifestation of acute GVHD. Skin biopsies may therefore be ideal for early detection of GVHD. Hepburn et al 13 have suggested that skin biopsies may support the diagnosis of GVHD of the liver and the digestive tract even in the absence of a rash.
Several studies have been performed to assess the value of skin biopsies, including in vitro skin explant models, in the diagnosis and management of acute GVHD. [14] [15] [16] [17] [18] [19] [20] These studies indicate that skin biopsies have been of limited value to confirm or predict the development of systemic GVHD that requires steroid treatment. Our main objective was to investigate with histopathological and immunohistochemical methods whether the source of stem cells might influence the development of GVHD, and thus possibly acquire new insight into the mechanisms involved.
Materials and methods

Patients
The skin biopsy study was initiated in May 1995 and was incorporated in a trial where 61 patients were randomised either to transplantation with BSC or BM, 31 and 30 patients, respectively. 7, 12 In all, 11 patients in the BSC group and 13 in the BM group did not give their consent to participate in the study. Thus, 37 patients were included in the skin biopsy study, 20 received BSC and 17 BM allografts. The characteristics of patients are provided in Table 1 .
Conditioning regimen, GVHD prophylaxis and treatment
The conditioning therapy was identical for all patients, consisting of busulphan 16 mg/kg b.w. and cyclophosphamide 120 mg/kg b.w. Patients with AML, FAB classification M4/M5 or ALL were given intrathecal methotrexate (12 mg), two doses before and four doses after transplantation. CNS radiation was not a part of the conditioning regimen.
GVHD prophylaxis consisted of cyclosporin A from day À1. In addition, methotrexate was administered intravenously (i.v.) 15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11 provided there was no severe liver toxicity. T-cell depletion was not performed. Steroids were not given unless the patients developed acute GVHD grade 2 or more. Acute GVHD was graded according to the Glucksberg criteria. 21 Chronic GVHD was classified as described by Shulman et al.
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Supportive care
Supportive care consisted of prophylactic administration of acyclovir from day À2 until day þ 28. The patients were given trimethoprim/sulphamethoxazol for 2 weeks prior to transplantation until day À4 and after transplantation when neutrophils exceeded 1.0 Â 10 9 /l and platelets 50 Â 10 9 /l. G-CSF was not given. All patients received antibiotics administered i.v. when fever occurred as well as transfusions and parenteral nutrition.
Study end points
The primary objective was to demonstrate possible histopathological and immunohistochemical differences in skin biopsies of patients allografted with haematopoietic stem cells from blood compared to BM. In addition, we wished to assess the value of sequential skin biopsies to predict the development of GVHD. Finally, we wanted to make a better distinction between changes due to acute GVHD and those caused by cytotoxic agents.
Skin biopsies
Punch biopsies (4 mm) were taken from clinically normal skin, in essence from the medial side of the thigh. They were performed on the day before the initiation of conditioning treatment (day À8), on the day of transplantation (day 0) and on days þ 14, þ 28 and þ 100. If skin rash appeared, an additional biopsy was taken from the affected skin unless the patient was discharged from hospital. The biopsies were fixed in formalin and processed routinely. In addition, serial sections of each biopsy were tested with a panel of monoclonal antibodies outlined in Table 2 . In brief, routinely fixed paraffin-embedded tissue sections were mounted on special Capillary Gap Microscope Slides and automatic immunostaining was carried out using a DAKO TechMate instrument 500 þ . Visualisation was by DAKO ChemMate Detection Kit using the labelled streptavidin-biotin method.
For each antibody, the positive cells were counted separately in the dermis and epidermis using a Â 50 objective. The whole of the epidermis and the upper two high-power fields ( Â 50) of the dermis and the number of positive cells expressed per high power field were counted.
The antibodies were purchased from DAKO Norge, Oslo, Norway, and Novocastra Laboratories Ltd, Smith Medical & Diagnostics, Å s, Norway. The total number of biopsies taken on the different days is shown in Table 3 . Additional biopsies were taken on six occasions from affected areas on patients with clinical skin GVHD.
Statistics
The number of observations for the different immunohistochemical variables was relatively small and their distribution was also relatively skewed. To compare different groups of the immunohistochemical variables, two-sided two-sample Wilcoxon's tests were used. Corrections for multiple tests were not performed. To model the Table 1 Clinical details Skin biopsies in assessing acute GVHD D Heldal et al change of the different immunohistochemical variables at day þ 14, þ 28 and þ 100, repeated measurement models were fitted, using the grouping variable as a betweensubject factor. For all response variables, the changes from day À8 to day þ 14, þ 28 and þ 100 were calculated and used in the repeated measurement models. The level of significance was 5%. The procedures in SPSS (SPSS, Chicago, IL, USA) and Splus (Insightful, Seattle, WA, USA) were used in the statistical analyses. The Regional Medical Research Ethics Committee, Southern Norway (REC II) approved the study, and written informed consent was obtained from all patients.
Results
Effects of myeloablative treatment
Skin biopsies taken before (day À8) and after (day 0) the conditioning treatment were compared. According to the Lerner classification, the histological assessment on day À8 showed grade 2 changes in two out of 37 specimens and grade 1 in eight. On day 0, nine out of 34 biopsies presented grade 1 changes. The remaining 52 biopsies (27 on day À8 and 25 on day 0) were normal. With regard to immunohistochemical findings, there was a significant reduction in the number of pan T cells in the epidermis (P ¼ 0.036) and a significantly increased number of proliferating epidermal cells, Ki67 (P ¼ 0.02), in the biopsies taken on day 0.
Impact of acute GVHD
Among the 20 patients who underwent transplantation with stem cells from blood, 10 patients developed clinically acute GVHD (median time of onset was 28 days, range 8-64). Of the 17 patients in the BM group, the corresponding number was two, but one of the patients withdrew his consent after day þ 14. Biopsies taken at the time of the outbreak of acute GVHD or a few days afterwards from affected skin of these patients (n ¼ 11) were compared with biopsies taken on day þ 28 from patients who did not develop clinical signs of acute GVHD (n ¼ 23).
Histological examination showed acute GVHD grade 3 in one biopsy only, grade 2 in five, grade 1 in three and grade 0 in two, while biopsies from non-GVHD patients on day þ 28 showed acute GVHD grade 2 in two, grade 1 in 11 and grade 0 in the remaining 10 biopsies.
Immunohistochemical examination of the same specimens showed a small but statistically significant increase in the number of T-lymphocytes both in the epidermis and dermis with the majority of these cells expressing the suppressor phenotype (CD8 þ ) as compared to biopsies from the non-GVHD patients. The number of CD68 þ macrophages in the dermis was also increased. There were only occasional cells expressing CD5, CD15 and CD16 antigen, and there were very few if any B cells or NK cells present. Two biopsies taken from affected skin showed HLA-DR positivity in keratinocytes. The number of Ki67 þ cells did not differ compared to the non-GVHD biopsies (Table 4) . Owing to the small number of BM patients with acute GVHD, a comparison between the groups could not be carried out.
In order to investigate changes that might serve as early markers of acute GVHD biopsies taken before the outbreak of skin rash (n ¼ 9) were compared with biopsies taken on day þ 28 from patients without acute GVHD (n ¼ 23). There was no statistically significant difference in the number or distribution of the cell populations that were studied.
A comparison between biopsies on day þ 28 from patients without acute GVHD transplanted with BSC (n ¼ 8) and BM (n ¼ 15) was also performed. The only difference between the groups was the number of macrophages in the epidermis, which was significantly higher among BSC recipients (P ¼ 0.016), median 0.04 (range 0.0-0.3) and 0.0 (range 0.0-0.08), respectively. On day þ 100, no difference was found between BSC (n ¼ 7) and BM recipients (n ¼ 12).
In the repeated measurement models, we found a statistically significant higher number of helper T cells in the epidermis in biopsies on days þ 14 and þ 28 (P ¼ 0.034), and an increase in the number of dendritic cells from days þ 14 to þ 100 (P ¼ 0.023) only in BSC recipients. Chronic GVHD
In the BSC group, 11 out of 20 patients and seven out of 17 in the BM group, developed chronic GVHD (median time 8 and 7 months after transplantation, respectively). At 100 days after transplantation, none of these patients presented clinical signs of GVHD. Skin biopsies from these patients performed at day þ 100 (nine in the BSC group and four in the BM group) were compared with biopsies from 14 patients who did not develop clinical signs of chronic GVHD (six and eight, respectively). There was no statistical difference between the histological or immunopathological profile. Thus, biopsies performed at day þ 100 could not predict the development of chronic GVHD, neither was there any convincing difference between biopsies taken from BSC and BM patients who later developed chronic GVHD.
Relapse/graft-versus-leukaemia
All relapses of leukaemia occurred after day þ 100 and all relapsed patients belonged to the BM group. A comparison between biopsies from relapsed (n ¼ 6) and nonrelapsed (n ¼ 21) irrespective of stem cell source was performed. NK cells were practically absent and could not be studied. No specific profile could be defined as predictive of relapse. A comparison between nonrelapsed BSC recipients (n ¼ 15) and nonrelapsed BM recipients (n ¼ 6) did not show any difference as judged in biopsies performed on day þ 100.
Comparison between histopathological and immunohistochemical findings
Nine out of 34 biopsies from unaffected skin, taken after the myeloablative treatment and before the infusion of stem cells, showed histopathological changes compatible with GVHD grade 1. Immunohistochemistry showed only elevated cell proliferation markers and a reduced number of pan T-lymphocytes. After transplantation, five biopsies showed grade 2 changes compatible with acute GVHD, but without clinical signs or an immunohistochemical pattern consistent with this condition. These patients did not develop GVHD at a later stage.
In patients with clinical manifestations of acute GVHD, the histopathological assessment according to the Lerner classification grade 3 or more, was consistent with the immunohistochemical pattern, showing a significantly higher number of T cells and macrophages in the dermis and epidermis.
Discussion
The main issue of this randomised trial was to compare skin biopsies of BSC and BM recipients with clinical GVHD. Unfortunately, the limited number of biopsies from patients with GVHD, in the BM group in particular, did not allow such assessment. Nevertheless, mainly based on previous studies of skin biopsies from BM recipients, 13- 16,24-26 our study indicates that skin biopsies from normal skin and affected skin caused by acute GVHD do not show a different pattern in BSC-transplanted patients compared to BM when studied with histopathological and immunohistochemical methods.
Histopathology of skin biopsies performed after conditioning and allografting is difficult to interpret. Changes caused by cytotoxic agents can easily be taken as evidence of a moderate acute GVHD. In some biopsies taken immediately after conditioning therapy, the histopathological findings showed grade 1-2 changes consistent with a mild acute GVHD, changes obviously not caused by GVHD since the biopsies were performed on days À8 and 0. In contrast, the immunohistochemical picture showed a reduced number of T cells in the epidermis and Table 4 Immunohistochemical assessment of lymphoid infiltration in skin biopsies from patients with clinically acute GVHD (biopsies taken at the time of the outbreak of acute GVHD or a few days afterwards depending on an outpatient appointment) or without acute GVHD (day +28)
Acute GVHD median (range) n ¼ 11
Non-GVHD median (range) n ¼ 23 P-value an increased number of proliferating keratinocytes. This pattern was not seen in later biopsies taken from both normal and affected skin. Thus, immunohistochemistry may be helpful in discriminating a skin rash caused by cytotoxic agents from acute GVHD. However, histological changes beyond grade 2 according to the Lerner classification were consistent with the clinical picture of true GVHD and the immunohistochemical findings. Our study supports the previous studies that the diagnosis of acute GVHD can be improved by using a combination of conventional histology and immunohistochemistry on biopsies from patients with a rash. Esteban et al 14 concluded that immunohistochemical studies are of no additional help as adjuvant in the differential diagnosis of these conditions. However, the number of monoclonal antibodies employed was limited compared to our study. The presence of HLA-DR positivity of keratinocytes has been regarded as associated with acute GVHD, 27 assuming this to be an early feature of GVHD and to be useful when the changes are subtle with no inflammatory infiltrate. In our material, however, no biopsies with mild changes disclosed keratinocytes expressing HLA-DR antigen.
Can sequential skin biopsies predict acute and chronic GVHD? The answer is no. Biopsies taken 1-3 days before the onset of a rash could not predict the development of acute GVHD. Biopsies on day þ 100 did not show any reminiscences of acute GVHD. At that time no patient had clinical signs consistent with GVHD. Thus, biopsies taken on day þ 100 have no predictive value with regard to the development of chronic GVHD later. On the other hand, histologic findings of GVHD in skin biopsies on day þ 100 is one of the several predictive factors of subsequent development of clinical chronic GVHD according to Loughran et al. 28 It would be of interest if biopsies could distinguish between skin rash caused by drugs and GVHD. Surprisingly, in our material there was no suspected drug rash. Therefore, we must await further studies to find out whether immunochemistry may be helpful in differential diagnosis.
Since the immunohistochemical examination showed a different pattern between the two groups on days þ 14 and þ 28, indicating an enhanced immunologic state of readiness in the BSC allografted, one might expect an enhanced graft-versus-leukaemia effect in this group. As described previously, among the patients with high-risk disease, one patient relapsed in BSC group and 10 in the BM group. 12 The number of biopsies secured on day þ 100 was unfortunately too small to examine this further.
In conclusion, this study did not allow us to conclude as to whether the source of stem cells influences acute or chronic GVHD in BSC and BM recipients. However, no substantial differences in the histopathological or immunohistochemical pattern in skin biopsies from apparently normal skin have been disclosed. The immunohistochemical findings in skin affected by acute GVHD in BSC allografted do not differ from those previously described in BM-transplanted patients. In biopsies from skin involved in typical acute GVHD irrespective of stem cell source, a combination of conventional histopathology and immunohistochemistry improves the diagnostic certainty of this condition. Immunohistochemical changes caused by cytotoxic agents are different from those caused by acute GVHD. Sequential skin biopsies from normal skin have no predictive value.
